Edition:
India

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

27.10USD
2:29am IST
Change (% chg)

$-0.45 (-1.63%)
Prev Close
$27.55
Open
$27.45
Day's High
$27.70
Day's Low
$27.00
Volume
67,767
Avg. Vol
102,774
52-wk High
$36.35
52-wk Low
$16.30

Chart for

About

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $1,039.60
Shares Outstanding(Mil.): 30.89
Dividend: --
Yield (%): --

Financials

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY

08 Jan 2018

BRIEF-Regenxbio Provides Year-End 2017 Corporate Update

* - ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​

05 Jan 2018

BRIEF-Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II

* REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II

19 Dec 2017

BRIEF-Regenxbio reports third quarter financial results

* Regenxbio reports third quarter 2017 financial results and recent operational highlights

09 Nov 2017

BRIEF-RTW Investments reports 5 pct passive stake in Regenxbio

* RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2xkVMYD) Further company coverage:

06 Oct 2017

BRIEF-Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing

* Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 million-SEC filing

03 Oct 2017

BRIEF-Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

* Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

20 Sep 2017

BRIEF-Dimension Therapeutics says co's board determined proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

* Dimension Therapeutics - ‍Dimension board determines proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

19 Sep 2017

BRIEF-Regenxbio to acquire Dimension Therapeutics

* Dimension Therapeutics Inc says ‍boards of directors of both companies have unanimously approved transaction​

25 Aug 2017

Earnings vs. Estimates